Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).

Kawano N, Yoshida N, Kawano S, Arakawa F, Miyoshi H, Yamada K, Nakashima K, Yoshida S, Kuriyama T, Tochigi T, Nakaike T, Shimokawa T, Yamashita K, Marutsuka K, Mashiba K, Kikuchi I, Ohshima K.

Intern Med. 2019 Aug 1;58(15):2159-2166. doi: 10.2169/internalmedicine.2513-18. Epub 2019 Apr 17.

2.

Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.

Matsuda K, Miyoshi H, Hiraoka K, Hamada T, Nakashima K, Shiba N, Ohshima K.

Clin Orthop Relat Res. 2018 Sep;476(9):1848-1855. doi: 10.1097/CORR.0000000000000379.

3.

Clinicopathological analysis of immunohistochemical expression of retinoic acid-related orphan receptor-γt in peripheral T-cell lymphoma, not otherwise specified.

Yanagida E, Miyoshi H, Kawamoto K, Nakashima K, Matsuda K, Yamada K, Muto R, Nagafuji K, Seto M, Ohshima K.

Hum Pathol. 2018 Sep;79:86-92. doi: 10.1016/j.humpath.2018.05.002. Epub 2018 Jun 22.

PMID:
29775622
4.

Prognostic impact of GATA binding protein-3 expression in primary lung adenocarcinoma.

Hashiguchi T, Miyoshi H, Nakashima K, Yokoyama S, Matsumoto R, Murakami D, Mitsuoka M, Takamori S, Akagi Y, Ohshima K.

Hum Pathol. 2017 May;63:157-164. doi: 10.1016/j.humpath.2017.02.024. Epub 2017 Mar 16.

PMID:
28322854
5.

HTLV-1 Viral Factor HBZ Induces CCR4 to Promote T-cell Migration and Proliferation.

Sugata K, Yasunaga J, Kinosada H, Mitobe Y, Furuta R, Mahgoub M, Onishi C, Nakashima K, Ohshima K, Matsuoka M.

Cancer Res. 2016 Sep 1;76(17):5068-79. doi: 10.1158/0008-5472.CAN-16-0361. Epub 2016 Jul 11.

6.

Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.

Yokoyama S, Miyoshi H, Nakashima K, Shimono J, Hashiguchi T, Mitsuoka M, Takamori S, Akagi Y, Ohshima K.

Clin Cancer Res. 2016 Sep 15;22(18):4727-34. doi: 10.1158/1078-0432.CCR-16-0434. Epub 2016 May 10.

7.

Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.

Sasaki Y, Guo Y, Arakawa F, Miyoshi H, Yoshida N, Koga Y, Nakashima K, Kurita D, Niino D, Seto M, Ohshima K.

Hematol Oncol. 2017 Sep;35(3):329-334. doi: 10.1002/hon.2293. Epub 2016 Apr 4.

PMID:
27041734
8.

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.

Azuma K, Kawahara A, Sonoda K, Nakashima K, Tashiro K, Watari K, Izumi H, Kage M, Kuwano M, Ono M, Hoshino T.

Oncotarget. 2014 Aug 15;5(15):5908-19.

9.

Microarray analysis of gene expression by microdissected epidermis and dermis in mycosis fungoides and adult T-cell leukemia/lymphoma.

Hashikawa K, Yasumoto S, Nakashima K, Arakawa F, Kiyasu J, Kimura Y, Saruta H, Nakama T, Yasuda K, Tashiro K, Kuhara S, Hashimoto T, Ohshima K.

Int J Oncol. 2014 Sep;45(3):1200-8. doi: 10.3892/ijo.2014.2524. Epub 2014 Jun 26.

PMID:
24970722
10.

Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.

Azuma K, Okamoto I, Kawahara A, Taira T, Nakashima K, Hattori S, Kinoshita T, Takeda M, Nakagawa K, Takamori S, Kuwano M, Ono M, Kage M.

J Thorac Oncol. 2012 Jan;7(1):122-7. doi: 10.1097/JTO.0b013e31822eeba2.

11.

Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.

Kawahara A, Azuma K, Sumi A, Taira T, Nakashima K, Aikawa E, Abe H, Yamaguchi T, Takamori S, Akiba J, Kage M.

Lung Cancer. 2011 Oct;74(1):35-40. doi: 10.1016/j.lungcan.2011.02.002. Epub 2011 Mar 27.

PMID:
21444121
12.

Nuclear β-catenin expression in basal cell adenomas of salivary gland.

Kawahara A, Harada H, Abe H, Yamaguchi T, Taira T, Nakashima K, Mihashi H, Akiba J, Kage M.

J Oral Pathol Med. 2011 Jul;40(6):460-6. doi: 10.1111/j.1600-0714.2011.01010.x. Epub 2011 Feb 16.

PMID:
21323741
13.

Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer.

Kawahara A, Hattori S, Akiba J, Nakashima K, Taira T, Watari K, Hosoi F, Uba M, Basaki Y, Koufuji K, Shirouzu K, Akiyama S, Kuwano M, Kage M, Ono M.

Oncol Rep. 2010 Aug;24(2):405-15.

PMID:
20596627
14.

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.

Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, Aizawa H, Basaki Y, Kuwano M, Kage M, Mitsudomi T, Ono M.

Clin Cancer Res. 2010 Jun 15;16(12):3163-70. doi: 10.1158/1078-0432.CCR-09-3239. Epub 2010 Apr 27.

15.

The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer.

Kawahara A, Azuma K, Hattori S, Nakashima K, Basaki Y, Akiba J, Takamori S, Aizawa H, Yanagawa T, Izumi H, Kohno K, Kono S, Kage M, Kuwano M, Ono M.

Hum Pathol. 2010 Jul;41(7):951-9. doi: 10.1016/j.humpath.2009.12.007. Epub 2010 Mar 17.

PMID:
20236686
16.

Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.

Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, Shirouzu K, Kohno K, Yanagawa T, Yamana H, Nishio K, Ono M, Kuwano M, Kage M.

Cancer Res. 2008 Mar 1;68(5):1504-12. doi: 10.1158/0008-5472.CAN-07-2362.

Supplemental Content

Loading ...
Support Center